Safety of high dose bedaquiline treatment in patients with extensively drug-resistant tuberculosis
<title>Extract</title> Bedaquiline (Bdq) was authorised for the treatment of multidrug-resistant (MDR) tuberculosis (TB) in 2014 in Europe. It is part of the preferred BPaLM regimen (Bdq, pretomanid, linezolid (Lzd), moxifloxacin (Mfx)), of individualised MDR-TB treatment and new MDR-TB regimens recommended by the recently updated World Health Organization guidelines [1]. Most trials aiming to develop new regimens for drug-resistant TB include Bdq, making it the most important drug at present.
Authors
- David Krieger
- Torsten Bauer (ORCID: https://orcid.org/0000-0003-1275-7361)
- Brit Häcker
- Niklas Köhler (ORCID: https://orcid.org/0000-0002-1911-0379)
- Simon Daller
- Claudia Maria Denkinger (ORCID: https://orcid.org/0000-0002-7216-7067)
- Elham Khatamzas (ORCID: https://orcid.org/0000-0001-9253-1340)
- Ralf Otto-Knapp
- Christoph Lange (ORCID: https://orcid.org/0000-0002-9691-4741)
- Martin Macholz
- Michael Knappik
- Silke Polsfuß
- Martin Kuhns (ORCID: https://orcid.org/0000-0003-0360-8356)
- Manuel Peterka
Institutions
- Universität Hamburg (DE)
- Baylor College of Medicine (US)
- Heidelberg University (DE)
- Klinikum St. Georg (DE)
- University Hospital Heidelberg (DE)
- Gemeinsamer Bundesausschuss (DE)
- Klinik Hietzing (AT)
- Helios Klinikum Emil von Behring (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Center for Infection Research (DE)
- Research Center Borstel - Leibniz Lung Center (DE)
- Deutsche Lepra- und Tuberkulosehilfe (DE)
- Texas Children's Hospital (US)
- University of Lübeck (DE)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1183/13993003.01496-2025
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00